[Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?].
The neuropeptide cholecystokinin (CCK) and its receptors are highly expressed in brain regions important for cognitive functions, emotions and the initiation of movements. Two high-affinity receptors exist for CCK, the A-and B-type. A number of ligands are developed for these receptors. Evidence for the involvement of CCK and its receptors in the pathofysiology of neuropsychiatric disorders is discussed. In addition, we discuss the possible use of CCK receptors ligands in the treatment of such disorders.
Zachrisson
O
O
Institutionen för klinisk neurovetenskap, Karolinska institutet, Karolinska sjukhuset.
Lindefors
N
N
D001921:Brain / Q000378:metabolism; D006801:Humans; D008024:Ligands; D001523:Mental Disorders / Q000188:drug therapy* / Q000378:metabolism; D011619:Psychotropic Drugs / Q000378:metabolism / Q000627:therapeutic use*; D011949:Receptors, Cholecystokinin / Q000187:drug effects* / Q000378:metabolism
D008024:Ligands; D011619:Psychotropic Drugs; D011949:Receptors, Cholecystokinin
Kolecystokininreceptorer. Mål för morgondagens psykofarmaka?